NSGCTTNonseminomatous Germ Cell Testicular Tumor
References in periodicals archive ?
1/2] has been widely investigated, with the aim of identifying the 20-30% of patients with NSGCTT who fail to respond to therapy (46-48).
1/2], half-life; DT, doubling time; PSA, prostate-specific antigen; CEA, carcinoembryonic antigen; CA, cancer antigen; BPH, benign prostatic hyperplasia; hCG [beta], hCG [beta] subunit; and NSGCTT, nonseminomatous germ- cell testicular tumor.